Walleye Capital LLC Immunovant, Inc. Transaction History

Walleye Capital LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$30.27 - $43.79 $322,042 - $465,881	10,639 Added 217.34%	15,534 $501,000
Q4 2023 Feb 14, 2024	SELL	$31.31 - $44.19 $800,502 - $1.13 Million	-25,567 Reduced 83.93%	4,895 $206,000
Q3 2023 Nov 14, 2023	BUY	$18.55 - $39.96 $565,070 - $1.22 Million	30,462 New	30,462 $1.17 Million
Q4 2022 Feb 14, 2023	BUY	$6.59 - $17.75 $2.41 Million - $6.5 Million	366,270 Added 218.58%	533,840 $9.48 Million
Q3 2022 Nov 14, 2022	BUY	$3.93 - $6.37 $658,550 - $1.07 Million	167,570 New	167,570 $935,000
Q1 2022 May 16, 2022	SELL	$5.06 - $8.77 $166,757 - $289,024	-32,956 Closed	0 $0
Q4 2021 Mar 03, 2022	BUY	$7.33 - $9.32 $125,496 - $159,567	17,121 Added 108.12%	32,956 $280,000
Q3 2021 Nov 15, 2021	SELL	$7.01 - $11.37 $135,363 - $219,554	-19,310 Reduced 54.94%	15,835 $138,000
Q2 2021 Aug 16, 2021	SELL	$9.4 - $16.85 $44,565 - $79,885	-4,741 Reduced 11.89%	35,145 $371,000
Q1 2021 May 17, 2021	BUY	$13.08 - $49.6 $521,708 - $1.98 Million	39,886 New	39,886 $640,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.